Athersys (OTCPK:ATHX.Q) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ATHX.Q Stock Overview

A biotechnology company, focuses on the research and development activities in the field of regenerative medicine.

About the company

ATHX.Q fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 12.5% per year over past 5 years

Does not have a meaningful market cap ($6K)

Negative shareholders equity

Shareholders have been substantially diluted in the past year

+ 3 more risks

Athersys, Inc. Competitors

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

ObsEva

OTCPK:OBSE.F

US$11.7k

Mymetics

OTCPK:MYMX

US$151.0

Comera Life Sciences Holdings

OTCPK:CMRA

US$3.1k

Price History & Performance

Summary of all time highs, changes and price drops for Athersys
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.46
52 Week Low	US$0.000001
Beta	-1.23
11 Month Change	0%
3 Month Change	-99.97%
1 Year Change	-100.00%
33 Year Change	-100.00%
5 Year Change	-100.00%
Change since IPO	-100.00%

Recent updates

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Aug 16

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Aug 12

Kasey Rosado named interim CFO of Athersys

Aug 04

Athersys: Dead Man Walking

Jul 25

Athersys: Focus On Stroke

May 04

Athersys - Hero Or Zero Opportunity

Apr 18

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Jan 20

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Dec 30

Athersys: COVID-ARDS Is The Company's Most Important Target

Nov 25

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Aug 30

Athersys: Subgroup Analysis As A Masterstroke

Jul 29

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

May 28

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

Feb 27

Update On Athersys - Trying To Read Between The Lines

Feb 03

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

Feb 01

Athersys: Stem Cell Opportunity For Risk Tolerant Investors

Nov 12

Shareholder Returns

	ATHX.Q	US Biotechs	US Market
7D	0%	-0.4%	-1.2%
1Y	-100.0%	20.1%	30.6%

Return vs Industry: ATHX.Q underperformed the US Biotechs industry which returned 18.7% over the past year.

Return vs Market: ATHX.Q underperformed the US Market which returned 32.8% over the past year.

Price Volatility

Is ATHX.Q's price volatile compared to industry and market?
ATHX.Q volatility
ATHX.Q Average Weekly Movement	6,647.3%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: ATHX.Q's share price has been volatile over the past 3 months.

Volatility Over Time: ATHX.Q's weekly volatility has increased from 3185% to 6647% over the past year.

About the Company

Founded	Employees	CEO	Website
1995	24	n/a	www.athersys.com

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications.

Athersys, Inc. Fundamentals Summary

How do Athersys's earnings and revenue compare to its market cap?
ATHX.Q fundamental statistics
Market cap	US$6.17k
Earnings (TTM)	-US$37.51m
Revenue (TTM)	US$80.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ATHX.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATHX.Q income statement (TTM)
Revenue	US$80.00k
Cost of Revenue	US$18.78m
Gross Profit	-US$18.69m
Other Expenses	US$18.81m
Earnings	-US$37.51m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.61
Gross Margin	-23,368.75%
Net Profit Margin	-46,883.75%
Debt/Equity Ratio	-29.6%

How did ATHX.Q perform over the long term?

See historical performance and comparison

This company listing is no longer active

ATHX.Q Stock Overview

Rewards

Risk Analysis

Athersys, Inc. Competitors

OTCPK:INFI.Q

US$90.0

OTCPK:OBSE.F

US$11.7k

OTCPK:MYMX

US$151.0

OTCPK:CMRA

US$3.1k

Price History & Performance

Recent News & Updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Recent updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought US$55k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Kasey Rosado named interim CFO of Athersys

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys: Dead Man Walking

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

Athersys: Focus On Stroke

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67